Regeneron Pharmaceuticals, Inc. (REGN) Covered Calls
Regeneron Pharmaceuticals is a leading biotechnology company that discovers, develops, and commercializes medicines for serious diseases. The company uses proprietary technologies including VelociSuite for developing fully human monoclonal antibodies and genetically engineered mouse platforms. Regeneron markets blockbuster drugs for eye diseases, allergic conditions, cancer, and cardiovascular disorders.
You can sell covered calls on Regeneron Pharmaceuticals, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for REGN (prices last updated Fri 4:16 PM ET):
| Regeneron Pharmaceuticals, Inc. (REGN) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 759.86 | -5.07 | 741.00 | 759.29 | 563K | 18 | 81 |
| Covered Calls For Regeneron Pharmaceuticals, Inc. (REGN) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| Mar 20 | 760 | 19.10 | 740.19 | 2.6% | 63.3% | |
| Apr 17 | 760 | 40.50 | 718.79 | 5.6% | 47.5% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Core Business and Products
Regeneron is a fully integrated biopharmaceutical company with capabilities spanning drug discovery, development, manufacturing, and commercialization. The company's flagship product EYLEA is a leading treatment for wet age-related macular degeneration and other retinal diseases, generating substantial revenue globally. Dupixent, co-developed with Sanofi, is a blockbuster antibody treating atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis.
The company's portfolio includes Libtayo for certain skin cancers and non-small cell lung cancer, Praluent for cardiovascular disease (marketed with Sanofi), Evkeeza for homozygous familial hypercholesterolemia, and Inmazeb for Ebola virus infection. Regeneron's proprietary VelocImmune technology platform enables rapid generation of fully human monoclonal antibodies, providing a significant competitive advantage in antibody drug development. The company also collaborates with partners on oncology therapies and maintains a robust pipeline across multiple therapeutic areas including ophthalmology, immunology, oncology, cardiovascular, and metabolic diseases.
Competitive Landscape
Regeneron operates in the highly competitive biotechnology and pharmaceutical industry, facing competition from both large diversified pharmaceutical companies and specialized biotech firms. In ophthalmology, the company competes against Roche's Lucentis and its biosimilars. For immunology products like Dupixent, competitors include AbbVie with Rinvoq and Skyrizi, Johnson & Johnson with Stelara, and Amgen with various immunology assets.
In oncology, Regeneron faces intense competition from established players including Bristol Myers Squibb, Merck, and numerous emerging biotechnology companies developing novel cancer therapies. The cardiovascular market is dominated by generic statins and PCSK9 inhibitors from Amgen. Regeneron differentiates itself through its proprietary technology platforms that accelerate drug discovery, its strong track record of developing best-in-class or first-in-class therapies, and its capability to conduct large-scale human genetics research through partnerships. The company's financial strength enables substantial investment in research and development.
Strategic Outlook and Innovation
Regeneron continues to invest heavily in expanding its pipeline and advancing early-stage programs across multiple therapeutic modalities. The company is developing next-generation ophthalmology products including high-dose EYLEA formulations to extend dosing intervals and improve patient convenience. Expansion of Dupixent into additional indications remains a key growth driver, with ongoing clinical trials in various inflammatory and allergic conditions.
The company is advancing its oncology portfolio with bispecific antibodies and combination therapies, leveraging its antibody engineering expertise. Regeneron's collaboration with Sanofi provides access to global commercialization infrastructure and shared development costs for key programs. The company is also exploring emerging areas including cell therapies and RNA-based medicines. Strategic use of human genetics data to identify and validate drug targets positions Regeneron to improve development success rates and bring transformative therapies to patients with significant unmet medical needs.
| Top 10 Open Interest For Mar 20 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | NVDA covered calls | 6. | QQQ covered calls | 1. | CTMX covered calls | |
| 2. | SLV covered calls | 7. | EWZ covered calls | 2. | MRVL covered calls | |
| 3. | EEM covered calls | 8. | GLD covered calls | 3. | REPL covered calls | |
| 4. | SPY covered calls | 9. | FXI covered calls | 4. | QURE covered calls | |
| 5. | IBIT covered calls | 10. | SOFI covered calls | 5. | PATH covered calls | |
Want more examples? REGL Covered Calls | REI Covered Calls
Risk Disclosure: Trading options involves significant risk and is not suitable for all investors. The information provided on this website is for educational and informational purposes only and does not constitute financial, investment, tax, or legal advice. Nothing contained on this site is an offer to buy or sell, or a solicitation of an offer to buy or sell, any securities or financial instruments.
Covered Call Strategy Risks: While covered call writing is often considered a conservative options strategy, it is not without risk. By selling a covered call, you are limiting your potential upside profit from the underlying stock. You remain exposed to the full downside risk of owning the underlying stock. In the event of a significant decline in the stock price, the premium received may not be sufficient to offset your losses.
No Guarantee of Performance: Past performance is not indicative of future results. Any examples, calculations, or hypothetical scenarios presented on this site are for illustrative purposes only and do not guarantee future returns or outcomes. Market conditions, liquidity, and trading system failures can affect your ability to execute trades at desired prices.
You should consult with a qualified professional advisor and conduct your own due diligence before making any investment decisions. By using this website, you acknowledge that you are responsible for your own investment decisions and agree to release this site and its affiliates from any liability relating to your use of this information. See the OCC's Characteristics and Risks of Standardized Options for more info.
